Sorafenib - Bayer

Alternative Names: BAY 43-9006 Tosylate; BAY 54-9085; BAY-43-9006; BAY-439006-Tosylate-Salt; Nexavar; Sorafenib tosilate; Sorafenib tosylate

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Onyx Pharmaceuticals; University of Kentucky
Developer ACORN Research; Asan Medical Center; Bayer; Beth Israel Deaconess Medical Center; Charite of Berlin; Genentech; Indiana University; Indiana University School of Medicine; Karolinska University Hospital; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Center (Korea); National Cancer Institute (USA); Onyx Pharmaceuticals; Oregon Health & Science University; Takeda; Thomas Jefferson University; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Yale University
Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Pyridines; Small molecules
Mechanism of Action Angiogenesis inhibitors; Fms-like tyrosine kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase kinase inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c raf inhibitors; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Raf kinase inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Thyroid cancer; Liver cancer; Renal cell carcinoma
New Molecular Entity Yes

Marketed Liver cancer; Renal cell carcinoma; Thyroid cancer
Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Gastric cancer; Glioma; Head and neck cancer; Myelodysplastic syndromes; Neurofibromatosis 1; Oesophageal cancer; Ovarian cancer; Portal hypertension; Soft tissue sarcoma
Suspended Malignant melanoma; Prostate cancer
No development reported Acute promyelocytic leukaemia; Cancer; Colorectal cancer; Glioblastoma; Gliosarcoma; Mesothelioma; Neuroendocrine tumours; Pancreatic cancer; Solid tumours; Urogenital cancer
Discontinued Breast cancer; Germ cell and embryonal neoplasms; Germ cell cancer; HER2 negative breast cancer; Non-small cell lung cancer; Small cell lung cancer; Testicular cancer

26 Sep 2022 No development reported - Phase-II for Renal cell carcinoma (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Australia, New Zealand (PO)
04 Jun 2021 Efficacy and adverse events data from a phase II trial in thyroid cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
28 Jul 2020 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Germany (PO, Suspension)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com